Ryan Nipp to Pancreatic Neoplasms
This is a "connection" page, showing publications Ryan Nipp has written about Pancreatic Neoplasms.
Connection Strength
5.517
-
Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care. JCO Oncol Pract. 2024 Aug; 20(8):1012-1015.
Score: 0.604
-
Palliative and Supportive Care for Individuals with Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2022 10; 36(5):1053-1061.
Score: 0.540
-
Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. JCO Oncol Pract. 2022 10; 18(10):e1587-e1593.
Score: 0.532
-
Opioid Prescriptions and Survival in Pancreatic Cancer. JCO Oncol Pract. 2022 06; 18(6):e839-e842.
Score: 0.514
-
Communicating the Information Needed for Treatment Decision Making Among Patients With Pancreatic Cancer Receiving Preoperative Therapy. JCO Oncol Pract. 2022 Mar; 18(3):e313-e324.
Score: 0.505
-
Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. Cancer Med. 2021 10; 10(20):7152-7161.
Score: 0.502
-
Patterns and predictors of end-of-life care in older patients with pancreatic cancer. Cancer Med. 2018 12; 7(12):6401-6410.
Score: 0.413
-
Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018 02; 7(2):525-535.
Score: 0.390
-
Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189.
Score: 0.365
-
Predicting a response to FOLFIRINOX in pancreatic cancer. J Natl Cancer Inst. 2015 Aug; 107(8).
Score: 0.325
-
Implementation of ePROs Into Multidisciplinary Tumor Board Discussions for Patients With Pancreatic Cancer: The INSPIRE Intervention. J Natl Compr Canc Netw. 2024 Nov; 22(9):602-609.
Score: 0.156
-
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021 11; 2(11):1124-1135.
Score: 0.127
-
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
Score: 0.108
-
Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
Score: 0.106
-
Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist. 2019 07; 24(7):945-954.
Score: 0.104
-
Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4027-4034.
Score: 0.103
-
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661.
Score: 0.101
-
Health-related Quality of Life and Functional Outcomes in 5-year Survivors After Pancreaticoduodenectomy. Ann Surg. 2017 10; 266(4):685-692.
Score: 0.024